As interventional techniques continue to gain popularity in cardiothoracic surgery, familiarity and mastery of these techniques are increasingly important for trainees and early career surgeons.
ALERT!
This site is not optimized for Internet Explorer 8 (or older).
Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.
TAVR (TAVI)
July 24, 2025
With the improvement in survival rates for heart transplant recipients, cardiac valvular disease is more frequently being encountered in this group of patients. This includes conditions such as aortic stenosis and mitral regurgitation in the transplanted heart.
May 29, 2025
This article studied the use of both surgical aortic valve replacement (SAVR) and transcatheter aortic valve replacement (TAVR) in patients with low-flow, low-gradient aortic stenosis, including both classical and paradoxical variants of the condition.
May 15, 2025
Transcatheter aortic valve implantation (TAVI) has emerged as the treatment of choice for symptomatic severe aortic stenosis (AS) across the whole surgical risk spectrum.
May 1, 2025
Women with severe symptomatic aortic stenosis are underrepresented in clinical trials. The Randomized Research in Women All Comers with Aortic Stenosis (RHEIA) trial investigates the balance of benefits and risks of transcatheter aortic valve implantation (TAVI) compared to surgery in women.
April 24, 2025
The Evolut Low Risk trial demonstrated that transcatheter aortic valve replacement (TAVR) was noninferior to surgery for the primary endpoint of all-cause mortality or disabling stroke at two years. In this new publication, the authors report the five-year outcomes of the Evolut Low Risk trial.
January 9, 2025
The treatment of aortic valve disease has evolved, and it is expected that TAVR will be available to most patients in the next few years. However, TAVR with a bioprosthesis will continue to be indicated and used. It is well documented that the use of a small valve, particularly in young patients, presents clinical challenges.
November 26, 2024
This study compared outcomes between patients undergoing valve-in-valve transcatheter aortic valve replacement (ViV TAVR) and redo surgical aortic valve replacement (redo SAVR) using a retrospective analysis of institutional databases, which included data from 2013 to 2022 for TAVR and 2011 to 2022 for SAVR.
November 26, 2024
The EARLY TAVR trial investigators randomly assigned patients with asymptomatic severe aortic stenosis to undergo either early transfemoral transcatheter aortic valve replacement (TAVR) or clinical surveillance. The primary end point was a composite of death, stroke, or unplanned hospitalization for cardiovascular causes.
October 31, 2024
The role of transcatheter aortic valve replacement (TAVR) for the treatment of aortic stenosis in the pre- and post-lung transplant population is limited. This specific patient population is considered high risk for general anesthesia and for surgical aortic valve replacement.